Search

Your search keyword '"DEL GAIZO, F."' showing total 42 results
Start Over Author "DEL GAIZO, F."
42 results on '"DEL GAIZO, F."'

13. Total Anomalous Systemic Venous Drainage to the Left Atrium: A Rare Case of Left Atrial Hysomerism without Intra-Cardiac Defect

Author

Maria Teresa Palladino, Giuseppe Santoro, Mariagiovanna Russo, Del Gaizo F, and Caiainiello G

Subjects
medicine.medical_specialty, Sinus drainage, Heart disease, business.industry, Left atrium, Cardiac arrhythmia, Venous drainage, Arteriovenous malformation, medicine.disease, Surgery, medicine.anatomical_structure, Internal medicine, Rare case, medicine, Cardiology, business
Published
2015
Full Text
View/download PDF

14. 'Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials'

Author

COMELLA P, FRASCI G, AVALLONE A, COSTANZO R, GAMBARDELLA A, BIANCO M, BILANCIA D, BUZZI F, BARTOLUCCI R, CIOFFI R, MESSINA V, CARNICELLI P, DE CATALDIS G, DEL GAIZO F, DEL PRETE S, DI LULLO L, FARRIS A, PUTZU C, FILIPPELLI G, OLIVITO V, DIMA G, GUIDA M, IANNELLI A, CONDEMI G, MANCARELLA S, MAIORINO L, MUSICÒ M, MASSIDDA B, IONTA MT, MEREU E, MASULLO P, MUCI D, PACCAGNELLA A, PANZA N, VAGLICA M, ROSELLI M, MARIOTTI S, MILIA V, NATALE D, GHIANI M, BARBATO E., PALMERI, Sergio, COMELLA P, FRASCI G, AVALLONE A, COSTANZO R, GAMBARDELLA A, BIANCO M, BILANCIA D, BUZZI F, BARTOLUCCI R, CIOFFI R, MESSINA V, CARNICELLI P, DE CATALDIS G, DEL GAIZO F, DEL PRETE S, DI LULLO L, FARRIS A, PUTZU C, FILIPPELLI G, OLIVITO V, DIMA G, GUIDA M, IANNELLI A, CONDEMI G, MANCARELLA S, MAIORINO L, MUSICÒ M, MASSIDDA B, IONTA MT, MEREU E, MASULLO P, MUCI D, PACCAGNELLA A, PANZA N, PALMERI S, VAGLICA M, ROSELLI M, MARIOTTI S, MILIA V, NATALE D, GHIANI M, and BARBATO E

Subjects
Paclitaxel, Non-small cell lung cancer, Gemcitabine, Elderly patient
Abstract

We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2 months), and overall survival (OS, 11.1 months versus 9.1 months) resulted slightly prolonged for younger patients. However, only stage and performance status resulted independently affecting PFS and OS. In conclusion, paclitaxel plus gemcitabine were similarly tolerated and active in younger and elderly patients. This regimen should be considered an option for the management of fit elderly patients.

Published
2008

15. Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) vs gemcitabine (G) or paclitaxel (T) alone in elderly or unfit non-small cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial

Author

BIANCO, Andrea, Frasci G, Comella P, De Cataldis G, Del Gaizo F, Lorusso V, Panza N, Mazzarella G, Muci D, Buzzi F, Gambardella A, Marsico A. Comella G., Bianco, Andrea, Frasci, G, Comella, P, De Cataldis, G, Del Gaizo, F, Lorusso, V, Panza, N, Mazzarella, G, Muci, D, Buzzi, F, Gambardella, A, and Marsico, A. Comella G.

Published
2003

16. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group

Author

COMELLA P, CRUCITTA E, DE VITA, Ferdinando, DE LUCIA L, FARRIS A, DEL GAIZO F, PALMERI S, IANNELLI A, MANCARELLA S, TAFUTO S, MAIORINO L, BUZZI F, DE CATALDIS G, CASARETTI R, AVALLONE A, MONTELLA M, COMELLA G, CATALANO G, LORUSSO V, DE LENA M, BIGLIETTO M, SANNA G, SAROBBA MG, BELLI C, RUSSO A, PIZZARDI V, ACCURSO V, MUSCA A, GRAVINA A, LEOPALDI G, BRUNETTI C, MUCI D, LEO S, AVINO F, DE LUCA L, GRECO E, AIELLO C., ORDITURA, Michele, Comella, P, Crucitta, E, DE VITA, Ferdinando, DE LUCIA, L, Farris, A, DEL GAIZO, F, Palmeri, S, Iannelli, A, Mancarella, S, Tafuto, S, Maiorino, L, Buzzi, F, DE CATALDIS, G, Casaretti, R, Avallone, A, Montella, M, Comella, G, Orditura, Michele, Catalano, G, Lorusso, V, DE LENA, M, Biglietto, M, Sanna, G, Sarobba, Mg, Belli, C, Russo, A, Pizzardi, V, Accurso, V, Musca, A, Gravina, A, Leopaldi, G, Brunetti, C, Muci, D, Leo, S, Avino, F, DE LUCA, L, Greco, E, and Aiello, C.

Published
2002

17. Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation

Author

Di Salvo, G, primary, Castaldi, B, additional, Gala, S, additional, Baldini, L, additional, Del Gaizo, F, additional, D'Aiello, F A, additional, Mormile, A, additional, Rea, A, additional, Scognamiglio, G, additional, Pacileo, G, additional, Keating, S, additional, Fadel, B M, additional, Berrino, L, additional, Perna, A, additional, Russo, M G, additional, and Calabrò, R, additional

Published
2015
Full Text
View/download PDF

18. New insights in drug development for the non-small cell lung cancer therapy

Author

Carmine Ferrara, Falanga M, Cesare Gridelli, Giovanni Palazzolo, Del Gaizo F, Dario Nicolella, Paolo Maione, G. Colantuoni, Antonio Rossi, and Ciro Guerriero

Subjects
Oncology, Sorafenib, medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Cetuximab, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Erlotinib Hydrochloride, Gefitinib, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, neoplasms, Protein Kinase Inhibitors, Sunitinib, business.industry, Antibodies, Monoclonal, medicine.disease, respiratory tract diseases, ErbB Receptors, Drug Design, Quinazolines, Erlotinib, business, medicine.drug
Abstract

Non-small cell lung cancer (NSCLC) remains a major problem worldwide. Since most patients with NSCLC have advanced disease at diagnosis, to date, chemotherapy, with third-generation platinum-based doublets, represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. To date, erlotinib and gefitinib, epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors have been licensed, erlotinib worldwide and gefitinib in Asian countries, for refractory NSCLC. Currently, bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, is the only clinically available antiangiogenic agent licensed, in combination with carboplatin plus paclitaxel, for first-line therapy of advanced NSCLC patients in the United States. Several new biologic agents are being evaluated in clinical research and some of them, such as ZD6474, sorafenib and sunitinib, due to the reported preliminary results and the oral administration seem to be promising targeted agents for the treatment of NSCLC. Aim of this review is to discuss about the new insights in targeted agents development for the treatment of NSCLC patients.

Published
2008

20. MODERATED POSTER SESSION: Deformation and multimodality imaging in congenital heart: Thursday 4 December 2014, 08:30-18:00 * Location: Moderated Poster area

Author

West, C., primary, Garcia-Aranda Dominguez, B., additional, Alonso-Gonzalez, R., additional, Li, W., additional, Uebing, A., additional, Cruz, C., additional, Lebreiro, A., additional, Pinho, T., additional, Dias, C., additional, Silva Cardoso, J., additional, Julia Maciel, M., additional, Pirat, B., additional, Varan, B., additional, Erdogan, I., additional, Sade, L., additional, Muderrisoglu, H., additional, Mateescu, A., additional, Enache, R., additional, Nastase, O., additional, Botezatu, D., additional, Popescu, B., additional, Ginghina, C., additional, Di Salvo, G., additional, D'aiello, A., additional, Del Gaizo, F., additional, Rea, A., additional, Capogrosso, C., additional, Russo, M., additional, Capotosto, L., additional, D'angeli, I., additional, Placanica, A., additional, Ashurov, R., additional, Placanica, G., additional, Tanzilli, G., additional, Mangieri, E., additional, Vitarelli, A., additional, Grosse-Wortmann, L., additional, Compton, G., additional, Dragulescu, A., additional, Nield, L., additional, Ierano, P., additional, Esposito, R., additional, Santoro, C., additional, De Stefano, F., additional, Muscariello, R., additional, Buonauro, A., additional, Tufano, A., additional, Galderisi, M., additional, Cantinotti, M., additional, Assanta, N., additional, Crocetti, M., additional, Marotta, M., additional, Scalese, M., additional, Molinaro, S., additional, Murzi, B., additional, De Lucia, V., additional, Spadoni, I., additional, and Iervasi, G., additional

Published
2014
Full Text
View/download PDF

21. Poster session Thursday 6 December - AM: Other myocardial diseases

Author

Ojaghi-Haghighi, Z., primary, Mostafavi, A., additional, Moladoust, H., additional, Noohi, F., additional, Maleki, M., additional, Esmaeilzadeh, M., additional, Samiei, N., additional, Hosseini, S., additional, Jasaityte, R., additional, Teske, A., additional, Claus, P., additional, Verheyden, B., additional, Rademakers, F., additional, D'hooge, J., additional, Patrianakos, A., additional, Zacharaki, A., additional, Kalogerakis, A., additional, Nyktari, E., additional, Maniatakis, P., additional, Parthenakis, F., additional, Vardas, P., additional, Hilde, J. M., additional, Skjoerten, I., additional, Humerfelt, S., additional, Hansteen, V., additional, Melsom, M., additional, Hisdal, J., additional, Steine, K., additional, Ippolito, R., additional, Gripari, P., additional, Muraru, D., additional, Esposito, R., additional, Kocabay, G., additional, Tamborini, G., additional, Galderisi, M., additional, Maffessanti, F., additional, Badano, L., additional, Pepi, M., additional, Yurdakul, S., additional, Oner, F., additional, Sahin, T., additional, Avci, B., additional, Tayyareci, Y., additional, Direskeneli, H., additional, Aytekin, S., additional, Filali, T., additional, Jedaida, B., additional, Lahidheb, D., additional, Gommidh, M., additional, Mahfoudhi, H., additional, Hajlaoui, N., additional, Dahmani, R., additional, Fehri, W., additional, Haouala, H., additional, Andova, V., additional, Georgievska-Ismail, L., additional, Srbinovska-Kostovska, E., additional, Gardinger, Y., additional, Joanna Hlebowicz, J., additional, Ola Bjorgell, O., additional, Magnus Dencker, M., additional, Liao, M.-T., additional, Tsai, C.-T., additional, Lin, J.-L., additional, Piestrzeniewicz, K., additional, Luczak, K., additional, Maciejewski, M., additional, Komorowski, J., additional, Jankiewicz-Wika, J., additional, Drozdz, J., additional, Ismail, M. F., additional, Alasfar, A., additional, Elassal, M., additional, El-Sayed, S., additional, Ibraheim, M., additional, Dobrowolski, P., additional, Klisiewicz, A., additional, Florczak, E., additional, Prejbisz, A., additional, Szwench, E., additional, Rybicka, J., additional, Januszewicz, A., additional, Hoffman, P., additional, Santos Furtado, M., additional, Nogueira, K., additional, Arruda, A., additional, Rodrigues, A. C., additional, Carvalho, F., additional, Silva, M., additional, Cardoso, A., additional, Lira-Filho, E., additional, Pinheiro, J., additional, Andrade, J. L., additional, Mohammed, M., additional, Zito, C., additional, Cusma-Piccione, M., additional, Di Bella, G., additional, Taha, N., additional, Zagari, D., additional, Oteri, A., additional, Quattrone, A., additional, Boretti, I., additional, Carerj, S., additional, Obremska, O., additional, Boratynska, B., additional, Poczatek, P., additional, Zon, Z., additional, Magott, M., additional, Klinger, K., additional, Szenczi, O., additional, Szelid, Z., additional, Soos, P., additional, Bagyura, Z., additional, Edes, E., additional, Jozan, P., additional, Merkely, B., additional, Ahn, J., additional, Kim, D., additional, Jeon, D., additional, Kim, I., additional, Baeza Garzon, F., additional, Delgado, M., additional, Mesa, D., additional, Ruiz, M., additional, De Lezo, J. S., additional, Pan, M., additional, Leon, C., additional, Castillo, F., additional, Morenate, M., additional, Toledano, F., additional, Zhong, L., additional, Lim, E., additional, Shanmugam, N., additional, Law, S., additional, Ong, B., additional, Katwadi, K., additional, Tan, R., additional, Chua, Y., additional, Liew, R., additional, Ding, Z., additional, Von Bibra, H., additional, Leclerque, C., additional, Schuster, T., additional, Schumm-Draeger, P.-M., additional, Bonios, M., additional, Kaladaridou, A., additional, Papadopoulou, O., additional, Tasoulis, A., additional, Pamboucas, C., additional, Ntalianis, A., additional, Nanas, J., additional, Toumanidis, S., additional, Silva, D., additional, Cortez-Dias, N., additional, Carrilho-Ferreira, P., additional, Placido, R., additional, Jorge, C., additional, Calisto, C., additional, Robalo Martins, S., additional, Carvalho De Sousa, J., additional, Pinto, F., additional, Nunes Diogo, A., additional, Przewlocka-Kosmala, M., additional, Orda, A., additional, Karolko, B., additional, Mysiak, A., additional, Kosmala, W., additional, Moral Torres, S., additional, Rodriguez-Palomares, J., additional, Pineda, V., additional, Gruosso, D., additional, Evangelista, A., additional, Garcia-Dorado, D., additional, Figueras, J., additional, Cambronero, E., additional, Corbi, M. J., additional, Valle, A., additional, Cordoba, J., additional, Llanos, C., additional, Fernandez, M., additional, Lopez, I., additional, Hidalgo, V., additional, Barambio, M., additional, Jimenez, J., additional, D'andrea, A., additional, Riegler, L., additional, Cocchia, R., additional, Russo, M., additional, Bossone, E., additional, Calabro, R., additional, Iniesta Manjavacas, A., additional, Valbuena Lopez, S., additional, Lopez Fernandez, T., additional, Garcia-Blas, S., additional, De Torres Alba, F., additional, De Diego, J. G., additional, Ramirez Valdiris, U., additional, Mesa Garcia, J., additional, Moreno Yanguela, M., additional, Lopez-Sendon, J., additional, Logstrup, B., additional, Andersen, H., additional, Thuesen, L., additional, Christiansen, E., additional, Terp, K., additional, Klaaborg, K., additional, Poulsen, S., additional, Cacicedo, A., additional, Velasco, S., additional, Aguirre, U., additional, Onaindia, J., additional, Rodriguez, I., additional, Oria, G., additional, Subinas, A., additional, Zugazabeitia, G., additional, Romero, A., additional, Laraudogoitia Zaldumbide, E., additional, Weisz, S., additional, Magne, J., additional, Dulgheru, R., additional, Rosca, M., additional, Pierard, L., additional, Lancellotti, P., additional, Auffret, V., additional, Donal, E., additional, Bedossa, M., additional, Boulmier, D., additional, Laurent, M., additional, Verhoye, J., additional, Le Breton, H., additional, Van Hall, S., additional, Herbrand, T., additional, Ketterer, U., additional, Keymel, S., additional, Boering, Y., additional, Rassaf, T., additional, Meyer, C., additional, Zeus, T., additional, Kelm, M., additional, Balzer, J., additional, Floria, M., additional, Seldrum, S., additional, Mariciuc, M., additional, Laurence, G., additional, Buche, M., additional, Eucher, P., additional, Louagie, Y., additional, Jamart, J., additional, Marchandise, B., additional, Schroeder, E., additional, Venkatesh, A., additional, Sahlen, A., additional, Johnson, J., additional, Brodin, L., additional, Winter, R., additional, Shahgaldi, K., additional, Manouras, A., additional, Fusini, L., additional, Muratori, M., additional, Alamanni, F., additional, Bartorelli, A., additional, Ferrari, C., additional, Caiani, E., additional, Yaroslavskaya, E., additional, Kuznetsov, V., additional, Pushkarev, G., additional, Krinochkin, D., additional, Zyrianov, I., additional, Ciobotaru, C., additional, Kobayashi, Y., additional, Yamamoto, K., additional, Hirose, E., additional, Hirohata, A., additional, Ohe, T., additional, Jhund, P., additional, Cunningham, T., additional, Murday, V., additional, Findlay, I., additional, Sonecki, P., additional, Rangel, I., additional, Sousa, C., additional, Goncalves, A., additional, Correia, A., additional, Vigario, A., additional, Martins, E., additional, Silva-Cardoso, J., additional, Macedo, F., additional, Maciel, M., additional, Lovric, D., additional, Samardzic, J., additional, Milicic, D., additional, Reskovic, V., additional, Baricevic, Z., additional, Ivanac, I., additional, Separovic Hanzevacki, J., additional, Kim, K., additional, Song, J., additional, Jeong, H., additional, Yoon, H., additional, Ahn, Y., additional, Jeong, M., additional, Cho, J., additional, Park, J., additional, Kang, J., additional, Iorio, A., additional, Pinamonti, B., additional, Bobbo, M., additional, Merlo, M., additional, Barbati, G., additional, Massa, L., additional, Faganello, G., additional, Di Lenarda, A., additional, Sinagra, G., additional, Heggemann, F., additional, Hamm, K., additional, Streitner, F., additional, Sueselbeck, T., additional, Papavassiliu, T., additional, Borggrefe, M., additional, Haghi, D., additional, Ferreira, F., additional, Galrinho, A., additional, Soares, R., additional, Branco, L., additional, Abreu, J., additional, Feliciano, J., additional, Papoila, A., additional, Alves, M., additional, Leal, A., additional, Ferreira, R., additional, Reynaud, A., additional, Lund, L. H., additional, Oger, E., additional, Drouet, E., additional, Hage, C., additional, Bauer, F., additional, Linde, C., additional, Daubert, J., additional, Schnell, F., additional, Lentz, P., additional, Kervio, G., additional, Leurent, G., additional, Mabo, P., additional, Carre, F., additional, Rodrigues, A., additional, Roque, M., additional, Becker, D., additional, Barros, S., additional, Kay, F., additional, Emerick, T., additional, Sampaio-Barros, P., additional, Andrade, J., additional, Yamada, S., additional, Okada, K., additional, Iwano, H., additional, Nishino, H., additional, Nakabachi, M., additional, Yokoyama, S., additional, Kaga, S., additional, Mikami, T., additional, Tsutsui, H., additional, Mincu, R., additional, Magda, S., additional, Dumitrache Rujinski, S., additional, Constantinescu, T., additional, Mihaila, S., additional, Ciobanu, A., additional, Florescu, M., additional, Vinereanu, D., additional, Ashcheulova, T., additional, Kovalyova, O., additional, Ardeleanu, E., additional, Gurgus, D., additional, Gruici, A., additional, Suciu, R., additional, Ana, I., additional, Bergenzaun, L., additional, Ohlin, H., additional, Gudmundsson, P., additional, Willenheimer, R., additional, Chew, M., additional, Charalampopoulos, A., additional, Howard, L., additional, Davies, R., additional, Gin-Sing, W., additional, Tzoulaki, I., additional, Grapsa, I., additional, Gibbs, S., additional, Massabuau, P., additional, Weinert, L., additional, Lairez, O., additional, Berry, M., additional, Sotaquira, M., additional, Vaida, P., additional, Lang, R., additional, Khan, I., additional, Waterhouse, D., additional, Asegdom, S., additional, Alqaseer, M., additional, Foley, D., additional, Mcadam, B., additional, Colonna, P., additional, Michelotto, E., additional, Genco, W., additional, Rubino, M., additional, Pugliese, S., additional, Belfiore, A., additional, Sorino, M., additional, Trisorio Liuzzi, M., additional, Antonelli, G., additional, Palasciano, G., additional, Duszanska, A., additional, Skoczylas, I., additional, Streb, W., additional, Kukulski, T., additional, Polonski, L., additional, Kalarus, Z., additional, Fleig, A., additional, Seitz, K., additional, Secades, S., additional, Martin, M., additional, Corros, C., additional, Rodriguez, M., additional, De La Hera, J., additional, Garcia, A., additional, Velasco, E., additional, Fernandez, E., additional, Barriales, V., additional, Lambert, J., additional, Zwas, D. R., additional, Hoss, S., additional, Leibowitz, D., additional, Beeri, R., additional, Lotan, C., additional, Gilon, D., additional, Wierzbowska-Drabik, K., additional, Roszczyk, N., additional, Sobczak, M., additional, Plewka, M., additional, Chrzanowski, L., additional, Lipiec, P., additional, Kasprzak, J., additional, Wita, K., additional, Mizia-Stec, K., additional, Wrobel, W., additional, Plonska-Gosciniak, E., additional, Pinho, T., additional, Wang, Y., additional, Houle, H., additional, Madureira, A. J., additional, Zamorano, J., additional, Maciel, M. J., additional, Ancona, R., additional, Comenale Pinto, S., additional, Caso, P., additional, Coppola, M., additional, Rapisarda, O., additional, Calabro', R., additional, Cadenas Chamorro, R., additional, Lopez, T., additional, Gomez, J., additional, Moreno, M., additional, Salinas, P., additional, Jimenez Rubio, C., additional, Valbuena, S., additional, Manjavacas, A., additional, De Torres, F., additional, Vaugrenard, T., additional, Huttin, O., additional, Rouge, A., additional, Schwartz, J., additional, Zinzius, P., additional, Popovic, B., additional, Sellal, J., additional, Aliot, E., additional, Juilliere, Y., additional, Selton-Suty, C., additional, Looi, J., additional, Lee, A., additional, Hsiung, M., additional, Song, W., additional, Wong, R., additional, Underwood, M. J., additional, Fang, F., additional, Lin, Q., additional, Lam, Y., additional, Yu, C., additional, Vitarelli, A., additional, Nguyen, B., additional, Capotosto, L., additional, D-Alessandro, G., additional, D-Ascanio, M., additional, Rafique, A., additional, Gang, E., additional, Barilla, F., additional, Siegel, R., additional, Kydd, A., additional, Khan, F., additional, Watson, W., additional, Mccormick, L., additional, Virdee, M., additional, Dutka, D., additional, Ranjbar, S., additional, Karvandi, M., additional, Hassantash, S., additional, Grapsa, J., additional, Efthimiadis, I., additional, Pakrashi, T., additional, Dawson, D., additional, Punjabi, P., additional, Nihoyannopoulos, P., additional, Henein, M., additional, Soderberg, S., additional, Tossavainen, E., additional, Lindqvist, P., additional, Bellsham-Revell, H., additional, Bell, A., additional, Miller, O., additional, Simpson, J., additional, Altekin, E., additional, Kucuk, M., additional, Yanikoglu, A., additional, Karakas, S., additional, Er, A., additional, Ozel, D., additional, Ermis, C., additional, Demir, I., additional, Bajraktari, G., additional, Di Salvo, G., additional, Baldini, L., additional, Del Gaizo, F., additional, Rea, A., additional, Pergola, V., additional, Pacileo, G., additional, Fadel, B., additional, Seo, J.-S., additional, Choi, G.-N., additional, Jin, H.-Y., additional, Seol, S.-H., additional, Jang, J.-S., additional, Yang, T.-H., additional, Kim, D.-K., additional, Kim, D.-S., additional, Papadopoulou, E., additional, Hatzidou, S., additional, Agrios, J., additional, Pamboukas, C., additional, Antoniou, A., additional, Gargiulo, P., additional, Dellegrottaglie, S., additional, Bruzzese, D., additional, Scala, O., additional, D'amore, C., additional, Ruggiero, D., additional, Marciano, C., additional, Vassallo, E., additional, Pirozzi, E., additional, Perrone Filardi, P., additional, Mor-Avi, V., additional, Kachenoura, N., additional, Lodato, J., additional, Port, S., additional, Chandra, S., additional, Freed, B., additional, Bhave, N., additional, Newby, B., additional, Patel, A., additional, Dwivedi, G., additional, Alam, M., additional, Boczar, K., additional, Chow, B., additional, Staskiewicz, G., additional, Czekajska-Chehab, E., additional, Uhlig, S., additional, Tomaszewski, A., additional, Przegalinski, J., additional, Maciejewski, R., additional, Drop, A., additional, Di Giammarco, G., additional, Canosa, C., additional, Foschi, M., additional, Liberti, G., additional, Bedir, M., additional, Marinelli, D., additional, Masuyama, S., additional, Rabozzi, R., additional, Vijayan, S., additional, Miller, H., additional, Muthusamy, R., additional, Smith, S., additional, Gargani, L., additional, Pang, P., additional, Davis, E., additional, Schumacher, A., additional, Sicari, R., additional, Picano, E., additional, Chmiel, A., additional, Mizia, M., additional, Haberka, M., additional, Gieszczyk, K., additional, Sikora - Puz, A., additional, Lasota, B., additional, Trojnarska, O., additional, Grajek, S., additional, Gasior, Z., additional, Koumoulidis, A., additional, Vlasseros, I., additional, Tousoulis, D., additional, Katsi, V., additional, Avgeropoulou, A., additional, Divani, M., additional, Stefanadis, C., additional, and Kallikazaros, I., additional

Published
2012
Full Text
View/download PDF

22. Poster Session: Right ventricular systolic function

Author

Altman, M., primary, Bergerot, C., additional, Thibault, H., additional, Aussoleil, A., additional, Skuldadt Davidsen, E., additional, Barthelet, M., additional, Derumeaux, G. A., additional, Grapsa, J., additional, Zimbarra Cabrita, I., additional, Afilalo, J., additional, Paschou, S., additional, Dawson, D., additional, Durighel, G., additional, O'regan, D., additional, Howard, L., additional, Gibbs, J., additional, Nihoyannopoulos, P., additional, Morenate Navio, M., additional, Mesa Rubio, M., additional, Ortega, M. D., additional, Ruiz Ortiz, M., additional, Castillo Bernal, F., additional, Del Pino, C. L., additional, Toledano, F., additional, Alvarez-Ossorio, M. P., additional, Ojeda Pineda, S., additional, Lezo Cruz-Conde, J. S. D., additional, Jasaityte, R., additional, Claus, P., additional, Teske, A., additional, Herbots, L., additional, Verheyden, B., additional, Rademakers, F., additional, D'hooge, J., additional, Tocchetti, C. G., additional, Coppola, C., additional, Rea, D., additional, Quintavalle, C., additional, Guarino, L., additional, Castaldo, N., additional, De Lorenzo, C., additional, Condorelli, G., additional, Arra, C., additional, Maurea, N., additional, Voilliot, D., additional, Huttin, O., additional, Camara, Y., additional, Djaballah, W., additional, Carillo, S., additional, Zinzius, P., additional, Sellal, J., additional, Angioi, M., additional, Juilliere, Y., additional, Selton-Suty, C., additional, Dobrowolski, P., additional, Klisiewicz, A., additional, Florczak, E., additional, Prejbisz, A., additional, Szwench, E., additional, Rybicka, J., additional, Januszewicz, A., additional, Hoffman, P., additional, Jurado Roman, A., additional, De Dios Perez, S., additional, De Nicolas, J. M. M., additional, Diaz Anton, B., additional, Rubio Alonso, B., additional, Martin Asenjo, R., additional, Mayordomo Gomez, S., additional, Villagraz Tecedor, L., additional, Blazquez, L., additional, De Meneses, R. T., additional, Bernard, A., additional, Hernandez, A. I., additional, Reynaud, A., additional, Lerclercq, C., additional, Daubert, J., additional, Donal, E., additional, Arjan Singh, R., additional, Sivarani, S., additional, Lim, S., additional, Azman, W., additional, Almeida, M., additional, Cardim, N., additional, Fonseca, V., additional, Carmelo, V., additional, Santos, S., additional, Santos, T., additional, Toste, J., additional, Kosmala, W., additional, Orda, A., additional, Karolko, B., additional, Mysiak, A., additional, Przewlocka-Kosmala, M., additional, Farsalinos, K., additional, Tsiapras, D., additional, Kyrzopoulos, S., additional, Avramidou, E., additional, Vassilopoulou, D., additional, Voudris, V., additional, Hayrapetyan, H., additional, Adamyan, K., additional, Montero Cabezas, J., additional, Granda Nistal, C., additional, Garcia Aranda, B., additional, Sanchez Sanchez, V., additional, Sestito, A., additional, Lamendola, P., additional, Di Franco, A., additional, Lauria, C., additional, Lanza, G., additional, Kukucka, M., additional, Unbehaun, A., additional, Buz, S., additional, Mladenow, A., additional, Kuppe, H., additional, Pasic, M., additional, Habazettl, H., additional, Gemma, D., additional, Montoro Lopez, N., additional, De Celix, M. G. R., additional, Lopez Fernandez, T., additional, De Torres Alba, F., additional, Del Valle, D. I., additional, Ramirez, U., additional, Mesa, J., additional, Moreno Yanguela, M., additional, Lopez Sendon, J., additional, Eveborn, G. W., additional, Schirmer, H., additional, Lunde, P., additional, Heggelund, G., additional, Rasmussen, K., additional, Wang, Z., additional, Lasota, B., additional, Mizia-Stec, K., additional, Mizia, M., additional, Chmiel, A., additional, Adamczyk, T., additional, Chudek, J., additional, Gasior, Z., additional, Venkatesh, A., additional, Johnson, J., additional, Sahlen, A., additional, Brodin, L., additional, Winter, R., additional, Shahgaldi, K., additional, Manouras, A., additional, Valbuena, S., additional, Iniesta, A., additional, Lopez, T., additional, De Torres, F., additional, Salinas, P., additional, Garcia, S., additional, Moreno, M., additional, Lopez-Sendon, J., additional, Lebid, I., additional, Kobets, T., additional, Kuzmenko, T., additional, Katsanos, S., additional, Yiu, K., additional, Clavel, M., additional, Nina Ajmone, N., additional, Van Der Kley, F., additional, Rodes Cabau, J., additional, Schalij, M., additional, Bax, J., additional, Pibarot, P., additional, Delgado, V., additional, Fusini, L., additional, Tamborini, G., additional, Muratori, M., additional, Gripari, P., additional, Marsan, N., additional, Cefalu', C., additional, Ewe, S., additional, Maffessanti, F., additional, Pepi, M., additional, Hasselberg, N., additional, Haugaa, K., additional, Petri, H., additional, Berge, K., additional, Leren, T., additional, Bundgaard, H., additional, Edvardsen, T., additional, Ancona, R., additional, Comenale Pinto, S., additional, Caso, P., additional, Coppola, M., additional, Rapisarda, O., additional, Cavallaro, C., additional, Vecchione, F., additional, D'onofrio, A., additional, Calabro', R., additional, Rimbas, R., additional, Mihaila, S., additional, Enescu, O., additional, Patrascu, N., additional, Dragoi, R., additional, Rimbas, M., additional, Pop, C., additional, Vinereanu, D., additional, Gustafsson, S., additional, Morner, S., additional, Gronlund, C., additional, Suhr, O., additional, Lindqvist, P., additional, Di Bella, G., additional, Zito, C., additional, Minutoli, F., additional, Madaffari, A., additional, Cusma Piccione, M., additional, Mazzeo, A., additional, Massimo, R., additional, Pasquale, M., additional, Vita, G., additional, Carerj, S., additional, Rangel, I., additional, Goncalves, A., additional, Sousa, C., additional, Correia, A., additional, Martins, E., additional, Silva-Cardoso, J., additional, Macedo, F., additional, Maciel, M., additional, Pfeiffer, B., additional, Rigopoulos, A., additional, Seggewiss, H., additional, Alvarez Fuente, M., additional, Sainz Costa, T., additional, Medrano, C., additional, Navarro, M., additional, Blazquez Gamero, D., additional, Ramos, J., additional, Mellado, M., additional, De Jose, M., additional, Munoz, M., additional, Maroto, E., additional, Gargani, L., additional, Gosciniak, P., additional, Pratali, L., additional, Agoston, G., additional, Bruni, C., additional, Guiducci, S., additional, Matucci Cerinic, M., additional, Varga, A., additional, Sicari, R., additional, Picano, E., additional, Zhao, C., additional, Mei, M., additional, Yeung, C., additional, Siu, C., additional, Tse, H., additional, Florescu, M., additional, Magda, L., additional, Mincu, R., additional, Daha, I., additional, Stanescu, C. M., additional, Chirila, L., additional, Baicus, C., additional, Vlase, A., additional, Dan, G., additional, Montoro Lopez, M., additional, Florez Gomez, R., additional, Alonso Ladreda, A., additional, Itziar Soto, C., additional, Rios Blanco, J., additional, Guzman Martinez, G., additional, Lichodziejewska, B., additional, Kurnicka, K., additional, Goliszek, S., additional, Kostrubiec, M., additional, Dzikowska-Diduch, O., additional, Ciurzynski, M., additional, Labyk, A., additional, Krupa, M., additional, Palczewski, P., additional, Pruszczyk, P., additional, De Sousa, C. C., additional, Vigario, A., additional, Pinho, T., additional, Silva Cardoso, J., additional, Park, S.-J., additional, Song, J.-E., additional, Lee, Y.-J., additional, Ha, M.-R., additional, Chang, S.-A., additional, Choi, J.-O., additional, Lee, S.-C., additional, Park, S., additional, Oh, J., additional, Van De Bruaene, A., additional, De Meester, P., additional, Buys, R., additional, Vanhees, L., additional, Delcroix, M., additional, Voigt, J., additional, Budts, W., additional, Blundo, A., additional, Buccheri, S., additional, Monte, I. P., additional, Leggio, S., additional, Tamburino, C., additional, Sotaquira, M., additional, Lang, R., additional, Caiani, E., additional, Floria, M., additional, De Roy, L., additional, Xhaet, O., additional, Blommaert, D., additional, Jamart, J., additional, Gerard, M., additional, Deceuninck, O., additional, Marchandise, B., additional, Seldrum, S., additional, Schroeder, E., additional, Unsworth, B., additional, Sohaib, S., additional, Kulwant-Kaur, K., additional, Malcolme-Lawes, L., additional, Kanagaratnam, P., additional, Malik, I., additional, Ren, B., additional, Mulder, H., additional, Haak, A., additional, Van Stralen, M., additional, Szili-Torok, T., additional, Pluim, J., additional, Geleijnse, M., additional, Bosch, J., additional, Baglini, R., additional, Amaducci, A., additional, D'ancona, G., additional, Van Den Oord, S., additional, Akkus, Z., additional, Ten Kate, G., additional, Renaud, G., additional, Sijbrands, E., additional, De Jong, N., additional, Van Der Lugt, A., additional, Van Der Steen, A., additional, Schinkel, A., additional, Bjallmark, A., additional, Larsson, M., additional, Grishenkov, D., additional, Brodin, L.-A., additional, Brismar, T., additional, Paradossi, G., additional, Sveen, K. A., additional, Nerdrum, T., additional, Hanssen, K., additional, Dahl-Jorgensen, K., additional, Steine, K., additional, Cimino, S., additional, Pedrizzetti, G., additional, Tonti, G., additional, Canali, E., additional, Petronilli, V., additional, Cicogna, F., additional, Arcari, L., additional, De Luca, L., additional, Iacoboni, C., additional, Agati, L., additional, Abdel Moneim, S. S., additional, Eifert Rain, S., additional, Bernier, M., additional, Bhat, G., additional, Hagen, M., additional, Bott-Kitslaar, D., additional, Castello, R., additional, Wilansky, S., additional, Pellikka, P., additional, Mulvagh, S., additional, Delithanasis, I., additional, Celutkiene, J., additional, Kenny, C., additional, Monaghan, M., additional, Park, W., additional, Hong, G., additional, Son, J., additional, Lee, S., additional, Kim, U., additional, Park, J., additional, Shin, D., additional, Kim, Y., additional, Toutouzas, K., additional, Drakopoulou, M., additional, Aggeli, C., additional, Felekos, I., additional, Nikolaou, C., additional, Synetos, A., additional, Stathogiannis, K., additional, Tsiamis, E., additional, Siores, E., additional, Stefanadis, C., additional, Plicht, B., additional, Kahlert, P., additional, Grave, T., additional, Buck, T., additional, Konorza, T., additional, Gursoy, M., additional, Gokdeniz, T., additional, Astarcioglu, M., additional, Bayram, Z., additional, Cakal, B., additional, Karakoyun, S., additional, Kalcik, M., additional, Acar, R., additional, Kahveci, G., additional, Ozkan, M., additional, Tsang, W., additional, Weinert, L., additional, Yurdakul, S., additional, Avci, B., additional, Sahin, S., additional, Dilekci, B., additional, Aytekin, S., additional, Arenga, F., additional, Hascoet, S., additional, Martin, R., additional, Dulac, Y., additional, Peyre, M., additional, Benzouid, C., additional, Hadeed, K., additional, Acar, P., additional, Zakarkaite, D., additional, Skorniakov, V., additional, Zvironaite, V., additional, Grabauskiene, V., additional, Burca, J., additional, Ciparyte, L., additional, Laucevicius, A., additional, Di Salvo, G., additional, Rea, A., additional, D'aiello, A., additional, Del Gaizo, F., additional, Pergola, V., additional, D'andrea, A., additional, Pacileo, G., additional, Calabro, R., additional, Russo, M., additional, Dedobbeleer, C., additional, Hadefi, A., additional, Naeije, R., additional, Unger, P., additional, Mornos, C., additional, Cozma, D., additional, Ionac, A., additional, Mornos, A., additional, Valcovici, M., additional, Pescariu, S., additional, Petrescu, L., additional, Hu, K., additional, Liu, D., additional, Niemann, M., additional, Herrmann, S., additional, Cikes, M., additional, Stoerk, S., additional, Knop, S., additional, Ertl, G., additional, Bijnens, B., additional, Weidemann, F., additional, De Knegt, M., additional, Biering-Sorensen, T., additional, Sogaard, P., additional, Sivertsen, J., additional, Jensen, J., additional, Mogelvang, R., additional, Lam, W., additional, Tang, M., additional, Chan, K., additional, Yang, Y., additional, Fang, F., additional, Sun, J., additional, Yu, C., additional, Lam, Y., additional, Panoulas, V., additional, Sulemane, S., additional, Bratsas, A., additional, Konstantinou, K., additional, Francone, M., additional, Schau, T., additional, Seifert, M., additional, Ridjab, D., additional, Schoep, M., additional, Gottwald, M., additional, Neuss, M., additional, Meyhoefer, J., additional, Zaenker, M., additional, Butter, C., additional, Tarr, A., additional, Stoebe, S., additional, Pfeiffer, D., additional, Hagendorff, A., additional, Maret, E., additional, Ahlander, B.-M., additional, Bjorklund, P.-G., additional, Engvall, J., additional, Staskiewicz, G., additional, Czekajska-Chehab, E., additional, Adamczyk, P., additional, Siek, E., additional, Przybylski, P., additional, Maciejewski, R., additional, Drop, A., additional, Jimenez Rubio, C., additional, Isasti Aizpurua, G., additional, Miralles Ibarra, J., additional, Al-Mallah, M., additional, Somg, T., additional, Alam, S., additional, Chattahi, J., additional, Zweig, B., additional, Dhanalakota, K., additional, Boedeker, S., additional, Ananthasubramaniam, K., additional, Park, C., additional, March, K., additional, Jones, S., additional, Mayet, J., additional, Tillin, T., additional, Chaturvedi, N., additional, Hughes, A., additional, Hamodraka, E., additional, Kallistratos, E., additional, Karamanou, A., additional, Tsoukas, T., additional, Mavropoulos, D., additional, Kouremenos, N., additional, Zaharopoulou, I., additional, Nikolaidis, N., additional, Kremastinos, D., additional, Manolis, A., additional, Loboz-Rudnicka, M., additional, Jaroch, J., additional, Bociaga, Z., additional, Kruszynska, E., additional, Ciecierzynska, B., additional, Dziuba, M., additional, Dudek, K., additional, Uchmanowicz, I., additional, Loboz-Grudzien, K., additional, Silva, D., additional, Magalhaes, A., additional, Jorge, C., additional, Cortez-Dias, N., additional, Carrilho-Ferreira, P., additional, Silva Marques, J., additional, Portela, I., additional, Pascoa, C., additional, Nunes Diogo, A., additional, Brito, D., additional, Roosens, B., additional, Bala, G., additional, Droogmans, S., additional, Hostens, J., additional, Somja, J., additional, Delvenne, E., additional, Schiettecatte, J., additional, Lahoutte, T., additional, Van Camp, G., additional, and Cosyns, B., additional

Published
2012
Full Text
View/download PDF

30. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Author

PIGNATA S., SCAMBIA G., SAVARESE A., BREDA E., SCOLLO P., DE VIVO R., ROSSI E., GEBBIA V., NATALE D., DEL GAIZO F., NAGLIERI E., FERRO A., MUSSO P., D'ARCO A., SORIO R., PISANO C., DI MAIO M., ANNUNZIATA A., PERRONE F., MITO INVESTIGATORS . ., SIGNORIELLO, Giuseppe, Pignata, S., Scambia, G., Savarese, A., Breda, E., Scollo, P., DE VIVO, R., Rossi, E., Gebbia, V., Natale, D., DEL GAIZO, F., Naglieri, E., Ferro, A., Musso, P., D'Arco, A., Sorio, R., Pisano, C., DI MAIO, M., Signoriello, Giuseppe, Annunziata, A., Perrone, F., MITO INVESTIGATORS, . ., PIGNATA S, SCAMBIA G, SAVARESE A, BREDA E, SCOLLO P, DE VIVO R, ROSSI E, GEBBIA V, NATALE D, DEL GAIZO F, NAGLIERI E, FERRO A, MUSSO P, D'ARCO AM, SORIO, PISANO C, DI MAIO M, SIGNORIELLO G, ANNUNZIATA A, PERRONE F, MITO, and INVESTIGATORS

Subjects
Oncology, Cancer Research, endocrine system diseases, Settore MED/06 - Oncologia Medica, medicine.medical_treatment, PACLITAXEL, law.invention, Polyethylene Glycols, chemistry.chemical_compound, Randomized controlled trial, STAGE-III, law, CYCLOPHOSPHAMIDE, Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, STERICALLY STABILIZED LIPOSOMES, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Combined Modality Therapy, female genital diseases and pregnancy complications, Paclitaxel, MITO-2 randomized trial, carboplatin, SURVIVAL, Female, Chemical and Drug Induced Liver Injury, medicine.drug, Agranulocytosis, Research Article, Adult, medicine.medical_specialty, CARCINOMA, Ovariectomy, lcsh:RC254-282, Drug Administration Schedule, Drug Hypersensitivity, CISPLATIN, preliminary result, Internal medicine, medicine, Genetics, XENOGRAFTS, Humans, Doxorubicin, Paresthesia, neoplasms, METAANALYSIS, Aged, Chemotherapy, business.industry, Alopecia, medicine.disease, PHASE-III, Thrombocytopenia, Carboplatin, Surgery, Clinical trial, chemistry, Liposomes, Feasibility Studies, Topotecan, Ovarian cancer, business
Abstract

Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged < 75 years, ECOG performance status ≤ 2, were randomized to carboplatin AUC 5 plus paclitaxel 175 mg/m2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed in July 2004. Data from the first 50 patients treated with carboplatin plus pegylated liposomal doxorubicin were evaluated. Median age was 60 years (range 34–75). Forty-three patients (86%) completed 6 cycles. Two thirds of the patients had at least one cycle delayed due to toxicity, but 63% of the cycles were administered on time. In most cases the reason for chemotherapy delay was neutropenia or other hematological toxicity. No delay due to palmar-plantar erythrodysesthesia (PPE) was recorded. No toxic death was recorded. Reported hematological toxicities were: grade (G) 3 anemia 16%, G3/G4 neutropenia 36% and 10% respectively, G3/4 thrombocytopenia 22% and 4% respectively. Non-haematological toxicity was infrequent: pulmonary G1 6%, heart rhythm G1 4%, liver toxicity G1 6%, G2 4% and G3 2%. Complete hair loss was reported in 6% of patients, and G1 neuropathy in 2%. PPE was recorded in 14% of the cases (G1 10%, G2 2%, G3 2%). Conclusion This safety analysis shows that the adopted schedule of carboplatin plus pegylated liposomal doxorubicin given every 3 weeks is feasible as first line treatment in ovarian cancer patients, although 37% of the cycles were delayed due to haematological toxicity. Toxicities that are common with standard combination of carboplatin plus paclitaxel (neurotoxicity and hair loss) are infrequent with this experimental schedule, and skin toxicity appears manageable.

Full Text
View/download PDF

31. MODERATED POSTER SESSION: Deformation and multimodality imaging in congenital heart: Thursday 4 December 2014, 08:30-18:00 * Location: Moderated Poster area

Author

West, C, Garcia-Aranda Dominguez, B, Alonso-Gonzalez, R, Li, W, Uebing, A, Cruz, C, Lebreiro, A, Pinho, T, Dias, C, Silva Cardoso, J, Julia Maciel, M, Pirat, B, Varan, B, Erdogan, I, Sade, LE, Muderrisoglu, H, Cruz, C, Lebreiro, A, Pinho, T, Dias, C, Silva Cardoso, J, Julia Maciel, M, Mateescu, A, Enache, R, Nastase, O, Botezatu, D, Popescu, BA, Ginghina, C, Di Salvo, G, D'aiello, AF, Del Gaizo, F, Rea, A, Capogrosso, C, Russo, MG, Capotosto, L, D'angeli, I, Placanica, A, Ashurov, R, Placanica, G, Tanzilli, G, Mangieri, E, Vitarelli, A, Grosse-Wortmann, L, Compton, G, Dragulescu, A, Nield, L, Ierano, P, Esposito, R, Santoro, C, De Stefano, F, Muscariello, R, Buonauro, A, Tufano, A, Galderisi, M, Cantinotti, M, Assanta, N, Crocetti, M, Marotta, M, Scalese, M, Molinaro, S, Murzi, B, De Lucia, V, Spadoni, I, Iervasi, G, Gaisenok, O, Martsevich, S YU, and Deev, A D

Abstract

Aim: There is wealth of data on the echocardiographic evaluation of prosthetic valves in the aortic or mitral position. Similar data are missing for the Melody percutaneous pulmonary valve system (MPPV). We aimed to correlate the anatomic appearance of the MPPV with the haemodynamic result on invasive and echocardiographic assessment. Patients and Methods: All 45 patients who underwent MPPV implantation at our institution between 2007-2013 were studied (median age 30 [range 11-61] years). All patients had complex congenital heart disease. The narrowest dimensions of the MPPV system were taken from the final biplane orthogonal fluoroscopic images to calculate the effective valve opening area (EOA). The post implantation invasive peak-to-peak gradient (ΔPp-p) and the maximal and mean Doppler gradient (ΔPmax and ΔPmean) on the pre-discharge echocardiogram (within 72 hours of implantation) were also obtained. Results: ΔPp-p after valve implantation was low (11.5±5.2 [range 2-20] mmHg) and there was no significant residual pulmonary regurgitation. The peak and mean gradient across the valve by Doppler assessment were significantly higher than ΔPp-p (ΔPmean: 19.3±6.5, ΔPmax: 33.3±8.2 mmHg; P<0.0001 for both vs. ΔPp-p). Both Doppler gradients correlated significantly with the invasive peak gradient (ΔPp-p vs. ΔPmean: r=0.37, P=0.03; ΔPp-p vs. ΔPmax: r=0.39, P=0.02) The EOA of the valve system indexed to body surface area was 132±30 mm2/m2. There were only weak relationships between the indexed EOA and the invasive and Doppler gradients (correlations with EOA: ΔPp-p: r=-0.32, P=0.06; ΔPpeak: r=-0.33, P=0.045; ΔPmean: r=-0.23; P=0.16). Conclusion: Doppler assessment of the percutaneous Melody valve early after implantation consistently overestimates the invasive peak-to-peak gradient. Simple estimates of valve size do not allow prediction of central haemodynamics. These results reflect the complex and variable anatomy of the right ventricular outflow tract/ main pulmonary artery in this group of patients.

Published
2014
Full Text
View/download PDF

32. Aberrant right subclavian artery: the association with chromosomal defects and the related post-natal outcomes in a third level referral centre

Author

Carmela Morelli, Antonio Schiattarella, Adelaide Fusco, Maria Giovanna Russo, Gianfranco Moccia, Fortuna Del Gaizo, Federica De Fazio, Maddalena Morlando, Nicola Colacurci, Laura Di Pietto, Ludovica Spinelli Barrile, Pasquale De Franciscis, Morlando, M., Morelli, C., Del Gaizo, F., Fusco, A., De Fazio, F., Di Pietto, L., Moccia, G., Spinelli Barrile, L., Schiattarella, A., De Franciscis, P., Colacurci, N., and Russo, M. G.

Subjects
Heart Defects, Congenital, Pediatrics, medicine.medical_specialty, Down syndrome, arteria lusoria, Stridor, Cardiovascular Abnormalities, Dysphagia lusoria, Subclavian Artery, fetal echocardiography, Ultrasonography, Prenatal, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Aberrant right subclavian artery, dysphagia lusoria, medicine, Humans, Arteria lusoria, Referral and Consultation, 030219 obstetrics & reproductive medicine, medicine.diagnostic_test, Respiratory distress, business.industry, Infant, Newborn, Obstetrics and Gynecology, medicine.disease, Dysphagia, 030220 oncology & carcinogenesis, ARSA, Female, medicine.symptom, business, Trisomy, Fetal echocardiography
Abstract

Aberrant right subclavian artery (ARSA) is the most common embryologic abnormality of the aortic arch. The presence of ARSA has been previously associated with an increased risk of Down syndrome. ARSA at birth may be associated with dysphagia, respiratory distress and stridor and there is no clear evidence‐based management. The aim of this study was to describe the associations with chromosomal abnormalities and the postnatal outcome of fetuses diagnosed with ARSA. We analysed fetuses diagnosed antenatally with ARSA between January 2013 and September 2019 in the fetal echocardiography unit of the Hospital Monaldi, University ‘Vanvitelli’ of Naples, Italy. The results showed fifty fetuses diagnosed with ARSA, all confirmed after birth. The ARSA was an isolated finding in 46 fetuses (92%), while in 4 fetuses the ARSA was associated with other cardiac and/or extra-cardiac anomalies. Only one fetus was diagnosed with trisomy 21 (2%). In this fetus the ARSA was the only ultrasound anomaly identified. There were no cases necessitating referral due to the presence of compression symptoms at birth. The presence of ARSA was associated with trisomy 21 in the 2% of cases in our series and there were no neonatal complications due to airway compression at birth.IMPACT STATEMENTWhat is already known on this subject? Aberrant right subclavian artery (ARSA) is the most common embryologic abnormality of the aortich arch. ARSA at birth could be associated with dysphagia, respiratory distress and stridor and no evidence-based management of these fetuses has been described yet. The presence of ARSA has been previously associated with an increased risk of Down syndrome. What do the results of this study add? This study confirms known data on association with chromosomal defects and provides some original data on the absence of symptomatology due to tracheal compression with a postnatal follow-up up to three years of age. What are the implications of these findings for clinical practice and/or further research? Our findings suggest that in cases with adequate prenatal assessment performed by experienced clinicians, delivery can safely take place at local hospitals, with no need of referral soon after birth. The use of transthoracic echocardiography to confirm the diagnoses of ARSA after birth and to plan the next follow-up appointments can be supported.

Published
2021

33. Two-dimensional strain and atrial function: a study on patients after percutaneous closure of atrial septal defect

Author

Fortuna Del Gaizo, Antonello D'Andrea, Biagio Castaldi, Maria Giovanna Russo, Giovanni Di Salvo, Carmela Morelli, Raffaele Calabrò, Giuseppe Pacileo, Ettore Merlino, Giuseppe Limongelli, S Gala, DI SALVO, Giovanni, Pacileo, G, Castaldi, B, Gala, S, Morelli, C, D'Andrea, A, Limongelli, Giuseppe, DEL GAIZO, F, Merlino, E, Russo, Maria Giovanna, and Calabro', Raffaele

Subjects
Carotid Artery Diseases, Male, medicine.medical_specialty, Percutaneous, Statistics as Topic, Atrial septal defect, Strain rate, Two-dimensional strain, Aged, Carotid Arteries, Case-Control Studies, Female, Humans, Middle Aged, Ultrasonography, Contrast Media, Left atrium, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Systole, Atrium (architecture), business.industry, Peak systolic strain, General Medicine, medicine.anatomical_structure, Two dimensional strain, Cardiology, Cardiology and Cardiovascular Medicine, business, Interatrial septum
Abstract

Aims To assess the value of two-dimensional (2D) strain in assessing regional myocardial function along the atrial wall. Methods and results We studied 20 patients late after successful percutaneous atrial septal defect (ASD) closure. The analysis was performed for atrial longitudinal peak systolic strain on the interatrial septum, in correspondence of the device, and on the lateral wall of the left atrium. The speckle tracking indexes demonstrated almost the absence of any deformation on the Amplatzer ASD occluder, a bulky non-contractile element, passively moved by global heart motion. This study in a simple clinical model demonstrates that 2D strain is not influenced by global heart motion and tethering from adjacent segments and can also be used to study the regional atrial function. Moreover, both acquisition and post-processing times of 2D strain were very short, and the reproducibility was very good. Conclusion All these above-mentioned characteristics make the 2D strain a tool fully compatible with the clinical scanning, able to provide additional clinical information.

Published
2008
Full Text
View/download PDF

34. Aberrant right subclavian artery: the association with chromosomal defects and the related post-natal outcomes in a third level referral centre.

Author

Morlando M, Morelli C, Del Gaizo F, Fusco A, De Fazio F, Di Pietto L, Moccia G, Spinelli Barrile L, Schiattarella A, De Franciscis P, Colacurci N, and Russo MG

Subjects
Cardiovascular Abnormalities, Female, Humans, Infant, Newborn, Pregnancy, Referral and Consultation, Subclavian Artery abnormalities, Subclavian Artery diagnostic imaging, Heart Defects, Congenital, Ultrasonography, Prenatal
Abstract

Aberrant right subclavian artery (ARSA) is the most common embryologic abnormality of the aortic arch. The presence of ARSA has been previously associated with an increased risk of Down syndrome. ARSA at birth may be associated with dysphagia, respiratory distress and stridor and there is no clear evidence-based management. The aim of this study was to describe the associations with chromosomal abnormalities and the postnatal outcome of fetuses diagnosed with ARSA. We analysed fetuses diagnosed antenatally with ARSA between January 2013 and September 2019 in the fetal echocardiography unit of the Hospital Monaldi, University 'Vanvitelli' of Naples, Italy. The results showed fifty fetuses diagnosed with ARSA, all confirmed after birth. The ARSA was an isolated finding in 46 fetuses (92%), while in 4 fetuses the ARSA was associated with other cardiac and/or extra-cardiac anomalies. Only one fetus was diagnosed with trisomy 21 (2%). In this fetus the ARSA was the only ultrasound anomaly identified. There were no cases necessitating referral due to the presence of compression symptoms at birth. The presence of ARSA was associated with trisomy 21 in the 2% of cases in our series and there were no neonatal complications due to airway compression at birth.IMPACT STATEMENT What is already known on this subject? Aberrant right subclavian artery (ARSA) is the most common embryologic abnormality of the aortich arch. ARSA at birth could be associated with dysphagia, respiratory distress and stridor and no evidence-based management of these fetuses has been described yet. The presence of ARSA has been previously associated with an increased risk of Down syndrome. What do the results of this study add? This study confirms known data on association with chromosomal defects and provides some original data on the absence of symptomatology due to tracheal compression with a postnatal follow-up up to three years of age. What are the implications of these findings for clinical practice and/or further research? Our findings suggest that in cases with adequate prenatal assessment performed by experienced clinicians, delivery can safely take place at local hospitals, with no need of referral soon after birth. The use of transthoracic echocardiography to confirm the diagnoses of ARSA after birth and to plan the next follow-up appointments can be supported.

Published
2022
Full Text
View/download PDF

35. New insights in drug development for the non-small cell lung cancer therapy.

Author

Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, and Colantuoni G

Subjects
Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents chemical synthesis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cetuximab, Drug Design, ErbB Receptors antagonists & inhibitors, Erlotinib Hydrochloride, Gefitinib, Humans, Protein Kinase Inhibitors therapeutic use, Quinazolines therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
Abstract

Non-small cell lung cancer (NSCLC) remains a major problem worldwide. Since most patients with NSCLC have advanced disease at diagnosis, to date, chemotherapy, with third-generation platinum-based doublets, represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. To date, erlotinib and gefitinib, epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors have been licensed, erlotinib worldwide and gefitinib in Asian countries, for refractory NSCLC. Currently, bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, is the only clinically available antiangiogenic agent licensed, in combination with carboplatin plus paclitaxel, for first-line therapy of advanced NSCLC patients in the United States. Several new biologic agents are being evaluated in clinical research and some of them, such as ZD6474, sorafenib and sunitinib, due to the reported preliminary results and the oral administration seem to be promising targeted agents for the treatment of NSCLC. Aim of this review is to discuss about the new insights in targeted agents development for the treatment of NSCLC patients.

Published
2008
Full Text
View/download PDF

36. Erlotinib in non-small-cell lung cancer.

Author

Gridelli C, Rossi A, Maione P, Colantuoni G, Del Gaizo F, Ferrara C, Nicolella D, and Guerriero C

Subjects
Animals, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung epidemiology, Carcinoma, Non-Small-Cell Lung metabolism, Erlotinib Hydrochloride, Humans, Lung Neoplasms epidemiology, Lung Neoplasms metabolism, Protein Kinase Inhibitors pharmacokinetics, Protein Kinase Inhibitors therapeutic use, Quinazolines pharmacokinetics, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Quinazolines therapeutic use
Abstract

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is a common feature in solid malignancies, including non-small-cell lung cancer (NSCLC), and is associated with poor clinical prognosis. Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a significant improvement in median survival, quality of life and related symptoms in an unselected population of advanced NSCLC patients in the second- or third-line setting. Erlotinib is well tolerated (with common toxicities including rash and diarrhoea) when administered at a standard oral daily dose of 150 mg. Further investigations are ongoing to contribute to our understanding of the role of erlotinib in NSCLC treatment.

Published
2007
Full Text
View/download PDF

37. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.

Author

Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D, and Rossi A

Subjects
Adenocarcinoma drug therapy, Adenocarcinoma secondary, Adult, Aged, Brain Neoplasms drug therapy, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Erlotinib Hydrochloride, Female, Gefitinib, Humans, Lung Neoplasms pathology, Middle Aged, Prognosis, Survival Rate, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors antagonists & inhibitors, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Quinazolines adverse effects, Quinazolines therapeutic use
Abstract

Introduction: We report the cases of three patients with advanced non-small cell lung cancer responding to erlotinib after progression under gefitinib treatment., Methods: Three never-smoker women with advanced lung adenocarcinoma, two pretreated with chemotherapy and with gefitinib and one with gefitinib alone, received erlotinib in a daily dose of 150 mg. All three patients had disease progression and had achieved tumor control with gefitinib., Results: The first patient achieved partial response of lung lesions, the second had partial response of brain lesions and stable disease of lung and bone disease, and the third had partial response of brain lesions and stable disease of lung disease. At the time of this analysis, all three patients were still receiving treatment with erlotinib with no evidence of treatment failure after more than 13, 13, and 7 months, respectively. Erlotinib was generally well tolerated, with grade 1 skin toxicity recorded in two patients., Conclusions: Erlotinib may be effective in patients with non-small cell lung cancer who were previously and successfully treated with gefitinib. However, careful selection of these patients is needed.

Published
2007
Full Text
View/download PDF

38. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.

Author

Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, and Rossi A

Subjects
Clinical Trials as Topic, ErbB Receptors antagonists & inhibitors, Humans, Niacinamide analogs & derivatives, Phenylurea Compounds, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors, Sorafenib, Sunitinib, Vascular Endothelial Growth Factor A antagonists & inhibitors, Antineoplastic Agents therapeutic use, Benzenesulfonates therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Indoles therapeutic use, Lung Neoplasms drug therapy, Pyridines therapeutic use, Pyrroles therapeutic use
Abstract

Despite the optimization of chemotherapy regimens, treatment outcomes for advanced non-small cell lung cancer (NSCLC) are still considered to be disappointing. Thus, clinical research of new treatment strategies is warranted. Several targeted agents have been introduced into clinical trials in NSCLC, but to date, only a few of these new agents can offer hope of a substantial impact on the natural history of the disease. One of the main reasons for the failure of several clinical trials of targeted therapy in lung cancer is that there is multilevel cross-stimulation among the targets of the new biological agents along several pathways of signal transduction that lead to neoplastic events; blocking only one of these pathways, as most first-generation targeted agents do, allows others to act as salvage or escape mechanisms for cancer cells. Sorafenib and sunitinib are two oral multitargeted receptor tyrosine kinase inhibitors. Sorafenib is a multikinase inhibitor that inhibits the kinase activity of both C-RAF and B-RAF and targets the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and stem cell factor receptor [KIT]). Sunitinib is a multitargeted inhibitor of PDGFR, KIT, fms-like tyrosine kinase 3, and VEGFR. The kinases targeted and inhibited by sorafenib and sunitinib directly and indirectly regulate tumor growth, survival, and angiogenesis, and this might be expected to result in broad antitumor efficacy. Sorafenib and sunitinib have been approved by the U.S. Food and Drug Administration for the treatment of metastatic renal cell carcinoma; sunitinib has also been approved for the treatment of gastrointestinal stromal tumors. Their mechanism of action, preclinical data, and phase II studies suggest efficacy in the treatment of advanced NSCLC.

Published
2007
Full Text
View/download PDF

39. Treatment of small cell lung cancer in the elderly.

Author

Rossi A, Maione P, Colantuoni G, Guerriero C, Ferrara C, Del Gaizo F, Nicolella D, and Gridelli C

Subjects
Aged, Aging pathology, Carcinoma, Small Cell drug therapy, Disease Progression, Geriatric Assessment, Humans, Risk Factors, Survival Analysis, Carcinoma, Small Cell mortality, Geriatrics trends, Medical Oncology trends
Abstract

Small cell lung cancer (SCLC) accounts for approximately 20% of lung carcinomas. Chemotherapy is the cornerstone of treatment for SCLC. In limited disease, the median survival time is about 12-16 months, with a 4%-5% long-term survival rate; in extensive disease the median survival time is 7-11 months. More than 50% of lung cancer patients are diagnosed when they are over the age of 65, and about 30% are over 70. Elderly patients tolerate chemotherapy poorly compared with their younger counterparts, because of age-related progressive reductions in organ function and comorbidities. The standard therapy for limited disease is combined chemoradiotherapy, followed by prophylactic brain irradiation for patients achieving complete responses. In the elderly, the addition of radiotherapy to chemotherapy must be carefully evaluated, considering the slight survival benefit and potential for substantial toxicity incurred with this treatment. The best approach is to design clinical trials that specifically include geriatric assessment to develop active and well-tolerated chemotherapy regimens for elderly SCLC patients. Survival improvement for SCLC patients requires a better understanding of tumor biology and the subsequent development of novel therapeutic strategies. Several targeted agents have been introduced into clinical trials in SCLC, but a minority of these new agents offers a promise of improved outcomes, and negative results are reported more commonly than positive ones. This review focuses on the main issues in the treatment of elderly SCLC patients.

Published
2005
Full Text
View/download PDF

40. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.

Author

Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V, and Gridelli C

Subjects
Administration, Oral, Age Factors, Aged, Antineoplastic Agents administration & dosage, Comorbidity, Gefitinib, Humans, Kidney Failure, Chronic complications, Male, Quinazolines administration & dosage, Treatment Outcome, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms complications, Lung Neoplasms drug therapy, Quinazolines adverse effects, Quinazolines therapeutic use
Abstract

Objectives: Comorbidities often contraindicate any chemotherapy in non-small cell lung cancer (NSCLC) patients, even single-agent one. This is the case of chronic renal failure., Methods: Two elderly patients (age >70 years) affected by advanced non-small cell lung cancer and chronic renal failure were treated, as front-line treatment, with gefitinib (ZD1839--'Iressa') administered orally at the dose of 250 mg daily., Results: In both patients renal function was not impaired by the treatment with gefitinib and no severe toxicity was recorded. One patient reported a stable disease, lasted 141 days, with symptoms relief. In the other patient a mixed response was reported with one large pulmonary site responding to gefitinib, but with appearance of new small lung metastases. He is still alive at 359 days., Conclusions: Gefitinib resulted safety when administered to advanced NSCLC elderly patients affected by chronic renal failure. Gefitinib should be further evaluated as front-line treatment in a larger sample of such patients, in order to establish a therapeutic option for a sort of patients unsuitable for any chemotherapy.

Published
2005
Full Text
View/download PDF

41. Oral cytotoxic drugs.

Author

Gridelli C, Rossi A, Guerriero C, Nicolella D, Ferrara C, Del Gaizo F, Colantuoni G, Airoma G, and Maione P

Subjects
Administration, Oral, Bridged-Ring Compounds therapeutic use, Clinical Trials as Topic, Enzyme Inhibitors therapeutic use, Humans, Organoplatinum Compounds therapeutic use, Topotecan therapeutic use, Vinblastine therapeutic use, Vinorelbine, Antineoplastic Agents therapeutic use, Neoplasms drug therapy, Taxoids, Vinblastine analogs & derivatives
Published
2002

42. Chemotherapy of advanced NSCLC in the elderly.

Author

Gridelli C, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Colantuoni G, and Rossi A

Subjects
Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin administration & dosage, Carboplatin adverse effects, Cisplatin administration & dosage, Cisplatin adverse effects, Female, Humans, Male, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results